Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
D&D sees fibrosis improvements, MASH resolution on GLP-1 drug
D&D linked its GLP-1/glucagon drug to liver health improvements, keeping the Korean biotech in the hunt for a market already served by Novo's Wegovy.
Nick Paul Taylor
May 27, 2026 10:30am
Lilly’s triple-G drug drives deep weight loss in phase 3 trial
May 21, 2026 10:27am
Vincentage to chase Lilly to China regulators after obesity win
May 18, 2026 9:23am
New Hepta blood test could predict GLP-1 response
May 9, 2026 3:08am
‘No change’ for CagriSema as Novo ditches single-chamber device
May 6, 2026 4:40am
Boehringer links dual agonist to 16.6% weight loss in phase 3
Apr 28, 2026 4:00am
